selected publications
- Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output. Molecular therapy. Methods & clinical development. 2023 Academic Article GET IT
-
An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
The Journal of clinical investigation.
2022
Academic Article
GET IT
Times cited: 29 -
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Blood.
2022
Academic Article
GET IT
Times cited: 57 - A SNIPpet of safety: a Goldilocks approach in CAR-T therapy. Cell research. 2022 Comment GET IT
-
Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy.
Cancers.
2021
Academic Article
GET IT
Times cited: 16